Аннотация:
The task of treating bronchial asthma is a set of measures aimed at disease control and prevention of the risks, such as exacerbations, hospitalizations, airway remodeling, and adverse asthma outcomes. High prevalence of improperly controlled asthma requires the development of new treatment approaches. Tiotropium is the first anticholinergic agent that has been approved for use in children and adults as additional supportive care for patients with persistent symptoms, who receive at least inhaled glucocorticosteroids. In large randomized clinical trials, enrolling patients with moderate to severe asthma, add-on therapy with tiotropium has demonstrated to be efficacious in improving disease control and lung function, decreasing risk of exacerbation and slowing the worsening of disease. Tiotropium demonstrated to be non inferior compared to long-acting beta-agonists in the maintenance treatment along with medium to high doses of inhaled corticosteroids. The present article presents the m
Ключевые слова:
Bronchial asthma; Children; Muscarinic antagonists; Tiotropium bromide
tiotropium bromide; Article; asthma; human; pathophysiology
Колосова Н. Г. Наталья Георгиевна 1970-
Геппе Н. А. Наталья Анатольевна 1946-
Шахназарова М. Д. Марина Далгатовна 1967-
Kolosova N. G. Natal`ya Georgievna 1970-
Geppe N. A. Natal`ya Anatolyevna 1946-
Shakhnazarova M. D. Marina Dalgatovna 1967-
Role of long-acting anticholinergic drugs in the treatment of bronchial asthma in children
Текст визуальный непосредственный
Вопросы практической педиатрии
ООО "Издательство "Династия"
Т. 14, Вып. 3 С. 68-72
2019
Статья
Bronchial asthma Children Muscarinic antagonists Tiotropium bromide
tiotropium bromide Article asthma human pathophysiology
The task of treating bronchial asthma is a set of measures aimed at disease control and prevention of the risks, such as exacerbations, hospitalizations, airway remodeling, and adverse asthma outcomes. High prevalence of improperly controlled asthma requires the development of new treatment approaches. Tiotropium is the first anticholinergic agent that has been approved for use in children and adults as additional supportive care for patients with persistent symptoms, who receive at least inhaled glucocorticosteroids. In large randomized clinical trials, enrolling patients with moderate to severe asthma, add-on therapy with tiotropium has demonstrated to be efficacious in improving disease control and lung function, decreasing risk of exacerbation and slowing the worsening of disease. Tiotropium demonstrated to be non inferior compared to long-acting beta-agonists in the maintenance treatment along with medium to high doses of inhaled corticosteroids. The present article presents the m